医学
心肌梗塞
传统医学
中医药
内科学
植物疗法
重症监护医学
药理学
替代医学
病理
作者
Yong Wang,Weili Lin,Chun Li,Sarita Singhal,Gaurav Jain,Lixin Zhu,Linghui Lu,Ruixin Zhu,Wei Wang
标识
DOI:10.3389/fphar.2017.00098
摘要
Background Based on global gene expression profile, therapeutic effects of Qishenyiqi (QSYQ) on acute myocardial infarction (AMI) were investigated by integrated analysis at multiple levels including gene expression, pathways involved and functional community. Methods Sprague-Dawley (SD) rats were randomly divided into 3 groups: Sham-operated, AMI model (left anterior descending coronary artery ligation) and QSYQ-treated group. Cardiac tissues were obtained for digital gene expression. Sequencing and transcriptome analyses were performed collaboratively, including analyses of differential gene expression, gene co-expression network, targeted attack on network and network functional community. In this study, a new strategy known as keystone gene-based community significance analysis was also developed. Results Analysis of top keystone QSYQ-regulated genes indicated that QSYQ ameliorated ventricular remodeling (VR), which is an irreversible process of AMI. At pathway level, both well-known cardiovascular diseases and cardiac signaling pathways were enriched. The most remarkable finding was the novel therapeutic effects identified from functional community analysis. This included anti-inflammatory effects mediated via suppression of arachidonic acid lipoxygenase (LOX) pathway and elevation of nitric oxide (NO); and amelioration of dyslipidaemia mediated via fatty acid oxidation. The regulatory patterns of QSYQ on key genes were confirmed by western blot, immunohistochemistry analysis and measurement of plasma lipids, which has further validated the therapeutic effects proposed in this study. Conclusions QSYQ exerts multipronged therapeutic effects on AMI, by concurrently alleviating VR progression, attenuating inflammation induced by arachidonic acid LOX pathway and NO production; and ameliorating dyslipidaemia.
科研通智能强力驱动
Strongly Powered by AbleSci AI